These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 3686916

  • 1. [Rational combinations of hormonal and cytostatic agents in disseminated forms of breast cancer].
    Garin AM, Dmitrieva NV, Vyshinskaia GV, Lichintser MR.
    Vopr Onkol; 1987; 33(11):13-7. PubMed ID: 3686916
    [Abstract] [Full Text] [Related]

  • 2. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
    Viale G, Regan MM, Maiorano E, Mastropasqua MG, Golouh R, Perin T, Brown RW, Kovács A, Pillay K, Ohlschlegel C, Braye S, Grigolato P, Rusca T, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA, Coates AS.
    J Clin Oncol; 2008 Mar 20; 26(9):1404-10. PubMed ID: 18349391
    [Abstract] [Full Text] [Related]

  • 3. Effect of tamoxifen after chemotherapy in hormone receptor-positive, node-negative breast cancer.
    Panasci LC.
    J Clin Oncol; 2006 May 20; 24(15):2392; author reply 2392. PubMed ID: 16710042
    [No Abstract] [Full Text] [Related]

  • 4. Modulation of molecular marker expression by induction chemotherapy in locally advanced breast cancer: correlation with the response to therapy and the expression of MDR1 and LRP.
    Schneider J, Lucas R, Sánchez J, Ruibal A, Tejerina A, Martín M.
    Anticancer Res; 2000 May 20; 20(6B):4373-7. PubMed ID: 11205274
    [Abstract] [Full Text] [Related]

  • 5. Progesterone receptor status of breast cancer metastases.
    Branković-Magić M, Janković R, Nesković-Konstantinović Z, Nikolić-Vukosavljević D.
    J Cancer Res Clin Oncol; 2002 Jan 20; 128(1):55-60. PubMed ID: 11862473
    [Abstract] [Full Text] [Related]

  • 6. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188).
    Davidson NE, O'Neill AM, Vukov AM, Osborne CK, Martino S, White DR, Abeloff MD.
    J Clin Oncol; 2005 Sep 01; 23(25):5973-82. PubMed ID: 16087950
    [Abstract] [Full Text] [Related]

  • 7. [A case report of advanced breast cancer effectively treated by chemo-endocrine therapy with diethylstilbestrol diphosphate and cyclophosphamide].
    Hareyama M, Saito A, Oouchi A, Morita K.
    Gan To Kagaku Ryoho; 1989 Jul 01; 16(7):2453-6. PubMed ID: 2751322
    [Abstract] [Full Text] [Related]

  • 8. Thymidine kinase and thymidylate synthase in advanced breast cancer: response to tamoxifen and chemotherapy.
    Foekens JA, Romain S, Look MP, Martin PM, Klijn JG.
    Cancer Res; 2001 Feb 15; 61(4):1421-5. PubMed ID: 11245445
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate).
    Schmid P, Untch M, Wallwiener D, Kossé V, Bondar G, Vassiljev L, Tarutinov V, Kienle E, Lüftner D, Possinger K, TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate).
    Anticancer Res; 2002 Feb 15; 22(4):2325-32. PubMed ID: 12174922
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Changes in microvessel density as assessed by CD34 antibodies after primary chemotherapy in human breast cancer.
    Bottini A, Berruti A, Bersiga A, Brizzi MP, Allevi G, Bolsi G, Aguggini S, Brunelli A, Betri E, Generali D, Scaratti L, Bertoli G, Alquati P, Dogliotti L.
    Clin Cancer Res; 2002 Jun 15; 8(6):1816-21. PubMed ID: 12060622
    [Abstract] [Full Text] [Related]

  • 16. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients.
    Bottini A, Berruti A, Bersiga A, Brizzi MP, Brunelli A, Gorzegno G, DiMarco B, Aguggini S, Bolsi G, Cirillo F, Filippini L, Betri E, Bertoli G, Alquati P, Dogliotti L.
    Clin Cancer Res; 2000 Jul 15; 6(7):2751-8. PubMed ID: 10914720
    [Abstract] [Full Text] [Related]

  • 17. Thirty-year follow-up of chemo/hormonal therapy in node-positive breast cancer.
    Gordon NH, Silverman P, Lasheen W, Meinert J, Siminoff LA.
    Breast Cancer Res Treat; 2007 May 15; 102(3):301-12. PubMed ID: 17033926
    [Abstract] [Full Text] [Related]

  • 18. Use of anti-oestrogen Zitazonium (tamoxifen) as adjuvant to cytostatic treatment in metastatic breast cancer.
    Palka I, Jávor J.
    Ther Hung; 1986 May 15; 34(4):217-23. PubMed ID: 3449976
    [No Abstract] [Full Text] [Related]

  • 19. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
    Berns EM, Foekens JA, Vossen R, Look MP, Devilee P, Henzen-Logmans SC, van Staveren IL, van Putten WL, Inganäs M, Meijer-van Gelder ME, Cornelisse C, Claassen CJ, Portengen H, Bakker B, Klijn JG.
    Cancer Res; 2000 Apr 15; 60(8):2155-62. PubMed ID: 10786679
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.